OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab075.035
Abstract: Endoscopic healing has become a critical treatment target in Crohn’s disease (CD). Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody against the p19 subunit of interleukin 23, is being investigated as a treatment for moderate-to-severe… read more here.
Keywords: response; endoscopic; moderate severe; motivate ... See more keywords
Clinical trial endpoints for patients with gliomas.
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-oncology practice"
DOI: 10.1093/nop/npw034
Abstract: Malignant glioma represents a diverse set of molecularly heterogeneous diseases. Few therapeutic agents have been approved despite decades of clinical trials research and pre-clinical investigation. Attempts to refine neuroimaging criteria and recent discovery of the… read more here.
Keywords: clinical trial; trial; oncology; endpoints patients ... See more keywords